Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus metronomic temozolomide in relapsed high-grade glioma
2007-000488-38Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and temozolomide in high-grade glioma (HGG), glioblastoma (GBM) and anaplastic astrocytoma (AA), sponsored by Academic Medical Center. Primary endpoints: Six-month progression-free survival (PFS6) and Safety. Started Feb 2007; status: active.
02
Drugs
bevacizumabtemozolomide
03
Conditions
high-grade glioma (HGG)glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on 2007-000488-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000488-38.